340 related articles for article (PubMed ID: 24097870)
1. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
[TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
Kim NY; Pyo JS
Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
[TBL] [Abstract][Full Text] [Related]
7. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
Xu XY; Lin N; Li YM; Zhi C; Shen H
Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
[TBL] [Abstract][Full Text] [Related]
8. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.
Noh SJ; Baek HA; Park HS; Jang KY; Moon WS; Kang MJ; Lee DG; Kim MH; Lee JH; Chung MJ
Pathol Res Pract; 2013 Jun; 209(6):365-70. PubMed ID: 23702379
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
10. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
11. Expression of p63, TTF-1 and Maspin in Non-Small Cell Lung Carcinoma and Their Effect on the Prognosis and Differential Diagnosis.
Yaman B; Nart D; Ekren PK; Çok G; Veral A
Turk Patoloji Derg; 2015; 31(3):163-74. PubMed ID: 26456962
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological significance of Lgr5 expression in lung adenocarcinoma.
Ryuge S; Sato Y; Jiang SX; Wang G; Kobayashi M; Nagashio R; Katono K; Iyoda A; Satoh Y; Masuda N
Lung Cancer; 2013 Oct; 82(1):143-8. PubMed ID: 23915911
[TBL] [Abstract][Full Text] [Related]
13. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer.
Cao X; Chen YZ; Luo RZ; Zhang L; Zhang SL; Zeng J; Jiang YC; Han YJ; Wen ZS
Oncotarget; 2015 May; 6(13):11704-13. PubMed ID: 25868976
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
Liu DC; Yang ZL
Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
[TBL] [Abstract][Full Text] [Related]
16. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study.
Tan D; Li Q; Deeb G; Ramnath N; Slocum HK; Brooks J; Cheney R; Wiseman S; Anderson T; Loewen G
Hum Pathol; 2003 Jun; 34(6):597-604. PubMed ID: 12827614
[TBL] [Abstract][Full Text] [Related]
17. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Kosma VM
Histol Histopathol; 2008 Jun; 23(6):693-700. PubMed ID: 18366007
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
